Experience

OrphAI Therapeutics

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Scientific Officer

  • Jan 2021 - 3 years

  Guilford, Connecticut, United States

• Head of Research & Translational Science

  • Feb 2017 - Jan 2021

  Guilford, CT



PresidioPath Consulting

• Biotech/Pharmaceutical Industry Consultant

  • 2009 - Feb 2017

  San Francisco & Greater New York City Area Provided strategic, operational and technical consulting services to Pharma and Biotech in multiple disease areas (including oncology, autoimmune, metabolic, anti-viral), platforms (small molecules, peptides, proteins) and supporting technologies (Including biomarkers and translational medicine). Clients include Affymax, KineMed, 3V Biosciences.



Resverlogix Corp.

• Canada
• Biotechnology
• 1 - 100 Employee

• Senior Vice President, Discovery Research

  • 2010 - 2013

  San Francisco/Calgary Identified the molecular target of Apabetalone/RVX-208, currently in a Phase III clinical trial for the treatment of atherosclerosis, as a selective BET inhibitor. Leveraged this knowledge to establish a drug discovery platform in epigenetics and expanded indications to include oncology and autoimmune disease. Led internal and external operations in support of drug discovery, development and translational medicine and identified a BET inhibitor IND candidate for the potential… Show more Identified the molecular target of Apabetalone/RVX-208, currently in a Phase III clinical trial for the treatment of atherosclerosis, as a selective BET inhibitor. Leveraged this knowledge to establish a drug discovery platform in epigenetics and expanded indications to include oncology and autoimmune disease. Led internal and external operations in support of drug discovery, development and translational medicine and identified a BET inhibitor IND candidate for the potential treatment of cancer. All assets in oncology and autoimmune disease have been split out into a new company (Zenith Epigenetics). Show less



Affymax

• Vice President, Research

  • 2007 - 2009

  Palo Alto, Ca Led non-clinical chemistry, biology and pharmacology/toxicology to support development of Phase III product, peginesitide, subsequently approved for the treatment of anemia, and to drive pipeline of peptide-based drugs.



Genelabs Technologies

• Biotechnology Research
• 1 - 100 Employee

• Vice President, Biology

  • 2006 - 2007

  Redwood City, CA Led group focused on Hepatitis C Viral inhibitors, including assay development, screening, drug profiling, resistance profiling and mechanism, in support of partnerships with Gilead, Novartis and internal programs.



Celera Corporation

• United States
• Biotechnology Research
• 1 - 100 Employee

• Vice President, Biology

  • 2003 - 2006

  S. San Francisco, CA Led a team of ~65 scientists in support of drug discovery programs in cancer, autoimmune, cardiovascular and viral diseases. Built or expanded capabilities in target identification and validation, protein kinases, high throughput assays, pharmacology, biomarker discovery and translational medicine. Advanced 2 projects into Phase I clinical studies: HDAC inhibitor, abexinostat, currently in Phase II for follicular lymphoma; Cathepsin S inhibitor for psoriasis. Supervised… Show more Led a team of ~65 scientists in support of drug discovery programs in cancer, autoimmune, cardiovascular and viral diseases. Built or expanded capabilities in target identification and validation, protein kinases, high throughput assays, pharmacology, biomarker discovery and translational medicine. Advanced 2 projects into Phase I clinical studies: HDAC inhibitor, abexinostat, currently in Phase II for follicular lymphoma; Cathepsin S inhibitor for psoriasis. Supervised the discovery and initial characterization of the irreversible BTK inhibitor, ibrutinib (Imbruvica), which is approved for Mantle Cell Leukemia and Chronic Lymphocytic Leukemia. These programs subsequently out-licensed to Pharmacyclics and Virobay. Pharmacyclics was acquired by AbbVie for $21B on the basis of Imbruvica. Show less



Sugen Inc

• United States
• Biotechnology
• 1 - 100 Employee

• Vice President, Research

  • 2002 - 2003

  S. San Francisco, CA Led a team of ~45 scientists to validate and progress multiple signal transduction targets into Pharmacia oncology and autoimmune drug discovery pipelines. Working within Pharmacia Global Management teams, created a process for validation of new targets in oncology that served as a model for other therapeutic areas. Responsible for successful transfer of programs to other Pfizer sites upon site closure.



DuPont Pharmaceuticals

• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Director, Metabolic Diseases

  • 1999 - 2002

  Wilmington, DE Established new group to drive target identification and drug discovery in metabolic diseases with a focus on nuclear receptors and peripheral enzyme targets. Advanced PPARα agonist program for dyslipidemia into Lead Optimization.



SmithKline Beecham Corporation

• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Assistant/Associate Director, Molecular Immunology

  • 1989 - 1999

  King of Prussia, PA Initiated and co-managed collaboration with Ligand Pharmaceuticals that led to the discovery of the first orally active Tpo mimetic (Eltrombopag/PROMACTA) for Idiopathic Thrombocytopenic Purpura and other platelet disorders. Led or supported several programs including: the discovery and validation of p38 MAP kinase (CSBP) as a novel inflammatory disease target using reverse pharmacology, and progression of two p38 inhibitors into clinical trials an IL-8 receptor antagonist… Show more Initiated and co-managed collaboration with Ligand Pharmaceuticals that led to the discovery of the first orally active Tpo mimetic (Eltrombopag/PROMACTA) for Idiopathic Thrombocytopenic Purpura and other platelet disorders. Led or supported several programs including: the discovery and validation of p38 MAP kinase (CSBP) as a novel inflammatory disease target using reverse pharmacology, and progression of two p38 inhibitors into clinical trials an IL-8 receptor antagonist program that resulted in the first published small molecule chemokine receptor antagonist an anti-IL-5 monoclonal antibody program for asthma, which led to the product, Nucala/mepolizumab a humanized agonist monoclonal antibody to EpoR for anemia. Spearheaded the discovery and characterization of multiple novel cytokines and their receptors from genomics. Show less